Pharmacokinetics of Gallic Acid Following Single-Dose Administration of Triphala Formulation in Healthy Thai Subjects

Authors

  • Piracha Jumpa-ngern Chulabhorn International College of Medicine, Thammasat University, Pathum Thani 12120, Thailand
  • Somboon Kietinun Chulabhorn International College of Medicine, Thammasat University, Pathum Thani 12120, Thailand
  • Kusuma Sriyakul Chulabhorn International College of Medicine, Thammasat University, Pathum Thani 12120, Thailand
  • Parunkul Tungsukruthai Chulabhorn International College of Medicine, Thammasat University, Pathum Thani 12120, Thailand
  • Wiratchanee Mahavorasirikul Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathum Thani 12120, Thailand
  • Kesara Na-Bangchang Chulabhorn International College of Medicine, Thammasat University, Pathum Thani 12120, Thailand, Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathum Thani 12120, Thailand, Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Thammasat University, Pathum Thani 12120, Thailand

Abstract

Triphala is commonly used in Thai traditional medicine for the treatment of various health conditions. The present study investigated the pharmacokinetics of a single oral dose (2,000 and 4,000 mg) of an aqueous extract Triphala formulation in 32 healthy Thai subject. Venous blood samples were collected from each subject at specific time points and concentrations of gallic acid, the major active component of the formulation, were measured using LC-MS/MS. Plasma concentration-time profiles were analyzed by the model-independent approach. Triphala formulations at both dose levels were well tolerated in all subjects. The pharmacokinetics of gallic acid was dose-independent. The median value for maximum concentration (Cmax), area under the curve from zero time to 48 hours after dosing (AUC0-48hr) and total AUC (AUC0-∞) following 4,000 mg dose of Triphala were about twice that of the 2,000 mg dose (Cmax: 70.81 vs. 41.84 ng/mL, AUC0-48hr: 150.12 vs. 88.46 ng.hr/ml, and AUC0-∞: 151.87 vs. 91.78 ng· hr/ml, respectively). The median time to maximum concentration (tmax) and the terminal elimination half-life (t1/2z) was 1 hour for both dose levels. The study provides preliminary information on the pharmacokinetics of gallic acid in humans for further dose optimization of Triphala formulation in treating various health conditions.

Downloads

Download data is not yet available.

Downloads

Published

2022-03-28

How to Cite

Jumpa-ngern, P. ., Kietinun, S. ., Sriyakul, K. ., Tungsukruthai, P. ., Mahavorasirikul, W. ., & Na-Bangchang, K. . (2022). Pharmacokinetics of Gallic Acid Following Single-Dose Administration of Triphala Formulation in Healthy Thai Subjects. Science & Technology Asia, 27(1), 57–66. Retrieved from https://ph02.tci-thaijo.org/index.php/SciTechAsia/article/view/246318

Issue

Section

Biological sciences